medigraphic.com

2022, Number 2

<< Back Next >>

Enf Infec Microbiol 2022; 42 (2)

Epidemiological risk factors associated with lethality in patients with SARS-COV-2 at the ISSSTE Hospital in Durango

Galván MMF, Hernández ZLR, Ibarra TLS, Jaquez SA, López GIA, Lozano MEA, Meza CLA, Moreno SM, Rocha ÁR, Orona VÓI, Solís GL, Vargas VPE, Villegas PP

Language: Spanish
References: 24
Page: 47-53
PDF size: 259.84 Kb.


ABSTRACT

Introduction. At the end of 2019, an atypical pneumonia, later identified as a SARS-COV-2, was announced by China; it currently presents a lethality of 2.2% worldwide, 8.9% in Mexico and 6.8% in Durango; different risk factors have contributed to a fatal outcome.
Objective. To identify epidemiological risk factors associated with lethality in patients infected by SARS-COV-2 in an ISSSTE’S hospital.
Methods. Observational, cross-sectional and retrospective, cases and controls study from May to August 2020. There were 25 cases; they were matched by age and sex with a 1:2 ratio. The case was the patient who died and the control was the patient who did not die of SARS-COV-2 respectively, the diagnosis of SARS-COV-2 was by real time PCR. SPSS® V24 was used, descriptive statistics, student’s t, Fisher chi-square, odds ratio (RM ›1) with 95% CI and p ‹0.05 as statistical significance, the information obtained was protected.
Results. An average age of 57.5 years was obtained, 76% were men. It took 5.5 days for the cases to seek medical attention and 3.8 days for the controls. Hypertension, obesity and diabetes were the most prevalent comorbidities in the case group. The risk factors associated with lethality were obesity, chronic kidney disease, copd and cancer.
Conclusions. Lethality was higher in men, comorbidities were more prevalent in the case group and the main risk factor associated with a fatal outcome was obesity, followed by chronic kidney disease, cancer and COPD.


REFERENCES

  1. Du, R.H., Liang, L.R., Yang, C.Q., Wang, W., Cao, T.Z.,Li, M. et al., “Predictors of mortality for patients withcovid-19 pneumonia caused by sars-cov-2: a prospectivecohort study”, Eur Respir J, 2020, 55 (5): 2000524. doi:10.1183/13993003.00524-2020.

  2. La Vignera, S., Cannarella, R., Condorelli, R.A., Torre,F., Aversa, A. y Calogero, A.E., “Sex-specific sars-cov-2mortality: among hormone-modulated ace2 expression,risk of venous thromboembolism and hypovitaminosisd”, Int J Mol Sci, 2020, 21 (8): 2948. doi: 10.3390/ijms21082948.

  3. Espinosa, O.A., Zanetti, A.D.S., Antunes, E.F., Longhi,F.G., Matos, T.A. y Battaglini, P.F., “Prevalence of comorbiditiesin patients and mortality cases affected bysars-cov-2: a systematic review and meta-analysis”, RevInst Med Trop Sao Paulo, 2020, 62: e43. doi: 10.1590/S1678-9946202062043.

  4. Suárez, V., Suárez Quezada, M., Oros Ruiz, S. y Ronquillode Jesús, E., “Epidemiology of covid-19 in Mexico:from the 27th of February to the 30th of April 2020”, RevClin Esp, 2020, 220 (8): 463-471.

  5. who, “Coronavirus fisease (covid-19) dashboard”,2020. Disponible en: http://covid19.who.int/.

  6. Huang, C., Wang, Y., Li, X. et al., “Clinical features ofpatients infected with 2019 novel coronavirus in Wuhan,China”, The Lancet, 2020, 395: 497-506. doi: 10.1016/S0140-6736(20)30183-5.

  7. Chen, N., Zhou, M., Dong, X. et al., “Epidemiologicaland clinical characteristics of 99 cases of 2019 novelcoronavirus pneumonia in Wuhan, China: a descriptivestudy”, The Lancet, 2020, 395: 507-513. doi:10.1016/S0140-6736(20)30211-7.

  8. Wang, D., Hu, B., Hu, C. et al., “Clinical characteristicsof 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”, jama, 2020,323 (11): 1061-1069. doi: 10.1001/jama.2020.1585.

  9. Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J.,Zhou, M., Wu, B., Yang, Z., Zhang, C., Yue, J., Zhang, Z.,Renz, H., Liu, X., Xie, J., Xie, M. y Zhao, J., “Risk factorsfor severity and mortality in adult covid-19 in patients inWuhan”, J Allergy Clin Immunol, 2020, 146 (1): 110-118.doi: 10.1016/j.jaci.2020.04.006.

  10. Li, X., Wang, L., Yan, S., Yang, F., Xiang, L., Zhu,J., Shen, B. y Gong, Z., “Clinical characteristics of 25death cases with covid-19: a retrospective review ofmedical records in a single medical center, Wuhan,China”, Int J Infect Dis, 2020, 94: 28-132. doi: 10.1016/j.ijid.2020.03.053.

  11. era-edta Council, eracoda Working Group, “Chronickidney disease is a key risk factor for severe covid-19: acall to action by the era-edta”, Nephrology Dialysis Transplantation,2021, 36 (1): 87-94. Disponible en: https://doi.org/10.1093/ndt/gfaa314.

  12. Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G.et al., “Clinical characteristics of 113 deceased patientswith coronavirus disease 2019: retrospective study”,bmj, 2020, 368: m1091. doi: 10.1136/bmj.m1091.

  13. Korean Society of Infectious Diseases, Korean Societyof Pediatric Infectious Diseases, Korean Societyof Epidemiology, Korean Society for AntimicrobialTherapy y Korean Society for Healthcare-AssociatedInfection Control and Prevention, “Korea Centers forDisease Control and Prevention report on the epidemiologicalfeatures of coronavirus disease 2019 (covid-19):outbreak in the Republic of Korea from January 19 toMarch 2, 2020”, J Korean Med Sci, 2020, 35: e112. doi:10.3346/jkms.2020.35.e112.

  14. Borges do Nascimento, I.J., Cacic, N., Abdulazeem,H.M., Von Groote, T.C., Jayarajah, U., Weerasekara, I. etal., “Novel coronavirus infection (covid-19) in humans: ascoping review and meta-analysis”, J Clin Med, 2020,9: 941. doi: 10.3390/jcm9040941.

  15. Channappanavar, R., Fett, C., Mack, M., Ten Eyck,P.P., Meyerholz, D.K. y Perlman, S., “Sex-based differencesin susceptibility to severe acute respiratory syndromecoronavirus infection”, J Immunol, 2017, 198:4046-4053. doi: 10.4049/jimmunol.1601896.

  16. Hussain, A., Mahawar, K., Xia, Z., Yang, W. y El-Hasani,S., “Obesity and mortality of covid-19. Meta-analysis”,Obes Res Clin Pract, 2020, 14 (4): 295-300. doi:10.1016/j.orcp.2020.07.002.

  17. Rubio Herrera, M.A. y Bretón Lesmes, I., “Obesityin the covid era: a global health challenge”, EndocrinolDiabetes Nutr, 2021, 68 (2): 123-129. doi: 10. 1016/j. endinu.2020.10.001.

  18. Wang, B., Luo, Q., Zhang, W., Yu, S., Cheng, X., Wang,L. et al., “The involvement of chronic kidney disease andacute kidney injury in disease severity and mortality inpatients with covid-19: a meta-analysis”, Kidney BloodPress Res, 2021, 46 (1): 17-30. doi: 10.1159/000512211.

  19. Zhao, Q., Meng, M., Kumar, R., Wu, Y., Huang, J.,Lian, N. et al., “The impact of copd and smoking historyon the severity of covid-19: a systemic review and meta-analysis”, J Med Virol, 2020, 92 (10): 1915-1921. doi:10.1002/jmv.25889.

  20. Gupta, K., Gandhi, S., Mebane, A., Singh, A., Vishnuvardhan,N. y Patel, E., “Cancer patients and covid-19:mortality, serious complications, biomarkers, and waysforward”, Cancer Treat Res Commun, 2021, 26: 100285.doi: 10.1016/j.ctarc.2020.100285.

  21. De las Heras, B., Saini, K.S., Boyle, F., Ades, F., DeAzambuja, E., Bozovic-Spasojevic, I. et al., “Cancertreatment and research during the covid-19 pandemic:experience of the first 6 months”, Oncol Ther, 2020, 8(2): 171-182.

  22. Varikasuvu, S.R., Dutt, N., Thangappazham, B. yVarshney, S., “Diabetes and covid-19: a pooled analysisrelated to disease severity and mortality”, PrimCare Diabetes, 2021, 15 (1): 24-27. doi: 10.1016/j.pcd.2020.08.015.

  23. Wu, Z.H., Tang, Y. y Cheng, Q., “Diabetes increasesthe mortality of patients with covid-19: a meta-analysis”,Acta Diabetol, 2021, 58 (2): 139-144. doi: 10.1007/s00592-020-01546-0.

  24. Gao, C., Cai, Y., Zhang, K., Zhou, L., Zhang, Y., Zhang,X. et al., “Association of hypertension and antihypertensivetreatment with covid-19 mortality: a retrospectiveobservational study”, Eur Heart J, 2020, 41 (22): 2058-2066. doi: 10.1093/eurheartj/ehaa433.




2020     |     www.medigraphic.com